Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128542 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
A Phase 4 study of Hepatitis C Virus Infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 17
- Study locations
NCT02128542 is a Phase 4 study of Hepatitis C Virus Infection that has completed, run by Gilead Sciences. The registered enrollment target is 66 participants, below the 189-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (65% lower). The trial reports 17 study locations across 11 states.
The verdict
NCT02128542, a Phase 4 study of Hepatitis C Virus Infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV infection.
Conditions Studied
Interventions
- DRUG RBV
- DRUG Sofosbuvir
Study Locations (17)
California
- - Long Beach
- - Los Angeles
- - Palo Alto
- - San Diego
- - San Francisco
Pennsylvania
- - Philadelphia
- - Pittsburgh
Texas
- - Dallas
- - Houston
Connecticut
- - New Haven
Florida
- - Miami
Georgia
- - Decatur
Maryland
- - Baltimore
Missouri
- - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02128542
The ClinicalTrials.gov registry entry for NCT02128542 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (65% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which RBV is the first listed.
NCT02128542 reports 17 study locations spanning 11 distinct geographic areas - top geographies include California, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT02128542 about?
NCT02128542 is a clinical study titled "Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis". This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV infection.
What is the current status of trial NCT02128542?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2014-06. Estimated completion is 2015-06.
What conditions does trial NCT02128542 study?
This clinical trial studies the following conditions: Hepatitis C Virus Infection.
What interventions are being tested in trial NCT02128542?
The interventions under investigation include: RBV (DRUG), Sofosbuvir (DRUG).
Who is sponsoring clinical trial NCT02128542?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02128542 being conducted?
This trial has 17 study locations across California, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hepatitis C Tracker Study
RECRUITING · NA
-
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
COMPLETED · Phase 3
-
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
COMPLETED · Phase 3
-
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
COMPLETED · Phase 2
-
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.